Details of the Drug

General Information of Drug (ID: DM19GUH)

Drug Name
TVB-2640
Indication
Disease Entry ICD 11 Status REF
Astrocytoma 2A00.0Y Phase 2 [1]
Colon cancer 2B90.Z Phase 2 [1]
Non-alcoholic fatty liver disease DB92 Phase 2 [2]
Advanced solid tumour 2A00-2F9Z Phase 1 [3]
Cross-matching ID
PubChem CID
66548316
TTD ID
D0K9BV
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Fatty acid synthase (FASN) TT7AOUD FAS_HUMAN Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT03938246) Study of TVB 2640 in Subjects With Non-Alcoholic Steatohepatitis (NASH). U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT02223247) A Phase 1, First-In-Human Study of Escalating Doses of Oral TVB-2640 in Patients With Solid Tumors. U.S. National Institutes of Health.
4 Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation. ACS Med Chem Lett. 2013 January 10; 4(1): 113-117.